Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Shifa Biomedical Corp.
Headquarters: Malvern, PA, United States of America
Website: http://www.shifabiomedical.co...
Year Founded: 2006
Status: Private
BioCentury | May 15, 2021
Deals
May 14 Quick Takes: With PNH approval, Apellis’ development partner due for payouts; plus Vera, Kinnate, Nephraegis, Shifa, Grove and more
Now that FDA has approved Empaveli pegcetacoplan from Apellis Pharmaceuticals Inc. (NASDAQ:APLS) to treat paroxysmal nocturnal hemoglobinuria, the risk-sharing entity that funded Empaveli’s
BioCentury | May 13, 2021
Finance
Latest Garabedian-led Perceptive Xontogeny fund to deploy $515M in search of ‘transformational’ assets
New fund 2x the size of debut venture vehicle
BioCentury | Oct 5, 2015
Emerging Company Profile
Picking a PCSK9
Liphorus' oral PCSK9 inhibitors could be safer, more convenient than mAbs
BioCentury | Sep 21, 2015
Product Development
Alnylam's lipid sync
Why Alnylam, Medicines Co. think ALN-PCSsc could best anti-PCSK9s on adherence
BioCentury | Apr 30, 2012
Product Development
PCSK9 bandwagon
Small molecules, RNAi enter clinic in race to target PCSK9 for lipid lowering
Items per page:
1 - 7 of 7